Delcath Systems

DCTH · NASDAQ

$14.76+$0.19 (+1.30%)TodayMarket closed · Oct 21, 4:13 AM ET

Prev close $14.57

Latest news

Press releaseOct 19, 4:01 PM ETBusiness Wire
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
NewsOct 6, 5:31 AM ET
Delcath Systems Q2 2026 Earnings Call Transcript
Press releaseSep 11, 4:01 PM ETBusiness Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 31, 4:01 PM ETBusiness Wire
Delcath Systems to Participate in Upcoming Investor Conferences
NewsAug 6, 8:03 AM ET
Delcath Systems Q2 EPS $0.07 Beats $(0.09) Estimate, Sales $29.133M Beat $26.259M Estimate
Press releaseAug 6, 8:01 AM ETBusiness Wire
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Press releaseJul 28, 4:01 PM ETBusiness Wire
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Press releaseJul 23, 4:01 PM ETBusiness Wire
Delcath Systems to Host Second Quarter 2026 Earnings Call
Press releaseJul 16, 4:01 PM ETBusiness Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 9, 8:00 AM ETBusiness Wire
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Press releaseMay 26, 4:01 PM ETBusiness Wire
Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
Press releaseMay 15, 4:01 PM ETBusiness Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 12, 8:00 AM ETBusiness Wire
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NewsMay 7, 8:01 AM ET
Delcath Systems Q1 EPS $(0.03) Beats $(0.10) Estimate, Sales $24.994M Beat $23.383M Estimate
Press releaseMay 7, 8:00 AM ETBusiness Wire
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Press releaseMay 7, 7:00 AM ETBusiness Wire
Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026
Press releaseApr 23, 8:30 AM ETBusiness Wire
Delcath Systems to Host First Quarter 2026 Earnings Call
Press releaseApr 6, 8:30 AM ETBusiness Wire
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma
Press releaseApr 1, 8:30 AM ETBusiness Wire
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Press releaseMar 3, 8:00 AM ETBusiness Wire
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
NewsFeb 26, 8:02 AM ET
Delcath Systems Q4 Earnings Assessment
Press releaseFeb 26, 8:00 AM ETBusiness Wire
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
Press releaseFeb 12, 8:00 AM ETBusiness Wire
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call
Press releaseJan 27, 8:05 AM ETBusiness Wire
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Press releaseJan 21, 4:01 PM ETBusiness Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJan 9, 8:05 AM ETBusiness Wire
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Press releaseDec 31, 8:00 AM ETBusiness Wire
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
Press releaseDec 3, 4:01 PM ETBusiness Wire
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
NewsNov 26, 12:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
Press releaseNov 20, 4:01 PM ETBusiness Wire
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Press releaseNov 4, 8:00 AM ETBusiness Wire
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
Press releaseAug 19, 8:30 AM ETBusiness Wire
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
Press releaseAug 6, 8:00 AM ETBusiness Wire
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
NewsMay 8, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseMay 8, 7:30 AM ETBusiness Wire
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseApr 28, 8:30 AM ETBusiness Wire
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Press releaseMar 27, 4:45 PM ETGlobe Newswire
Beta Bionics Announces Board Appointment of Gerard Michel
Press releaseMar 6, 8:00 AM ETBusiness Wire
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
NewsJan 14, 8:01 AM ET
Analyst Expectations For Delcath Systems's Future
NewsDec 26, 7:45 AM ETAvi Kapoor
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
Press releaseDec 17, 2:00 PM ETBusiness Wire
Clear Street Launches Healthcare & Biotechnology Equity Research

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems Q2 2026 Earnings Call Transcript

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Q2 EPS $0.07 Beats $(0.09) Estimate, Sales $29.133M Beat $26.259M Estimate

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

Delcath Systems to Host Second Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems Q1 EPS $(0.03) Beats $(0.10) Estimate, Sales $24.994M Beat $23.383M Estimate

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems Q4 Earnings Assessment

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Earnings Scheduled For February 26, 2026

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

10 Health Care Stocks With Whale Alerts In Today's Session

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

12 Health Care Stocks Moving In Thursday's Intraday Session

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Earnings Scheduled For May 8, 2025

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Beta Bionics Announces Board Appointment of Gerard Michel

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Analyst Expectations For Delcath Systems's Future

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket

Clear Street Launches Healthcare & Biotechnology Equity Research